Histone acetylation and disease (original) (raw)

Abstract.

Differential acetylation of histones and transcription factors plays an important regulatory role in developmental processes, proliferation and differentiation. Aberrant acetylation or deacetylation leads to such diverse disorders as leukemia, epithelial cancers, fragile X syndrome and Rubinstein-Taybi syndrome. The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders. Current treatment strategies are discussed, which are still mostly limited to histone deacetylase inhibitors such as trichostatin A and butyrate.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. CNRS UPR 9079, IFC-01 André Lwoff, 7, rue Guy Moquet, 94801 Villejuif (France), Fax +33 1 49 58 33 07, e-mail: ahbellan@vjf.cnrs.fr, , , , , , FR
    S. Timmermann, H. Lehrmann, A. Polesskaya & A. Harel-Bellan

Authors

  1. S. Timmermann
    You can also search for this author inPubMed Google Scholar
  2. H. Lehrmann
    You can also search for this author inPubMed Google Scholar
  3. A. Polesskaya
    You can also search for this author inPubMed Google Scholar
  4. A. Harel-Bellan
    You can also search for this author inPubMed Google Scholar

Additional information

Rights and permissions

About this article

Cite this article

Timmermann, S., Lehrmann, H., Polesskaya, A. et al. Histone acetylation and disease.CMLS, Cell. Mol. Life Sci. 58, 728–736 (2001). https://doi.org/10.1007/PL00000896

Download citation